Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of General Psychiatry
Published in: Annals of General Psychiatry 1/2013

Open Access 01-12-2013 | Case report

Tandospirone, a 5-HT1A partial agonist is effective in treating anorexia nervosa: a case series

Authors: Kyoji Okita, Akihiro Shiina, Michiko Nakazato, Masaomi Iyo

Published in: Annals of General Psychiatry | Issue 1/2013

Login to get access

Abstract

This case report details the therapeutic effects of tandospirone on two patients with anorexia nervosa, one with the restricting subtype (ANR), and another with the binge-eating/purging subtype (ANBP). A 22-year-old female patient with ANR and a 23-year-old female patient with ANBP were treated successfully with the 5-HT1A partial agonist tandospirone. After treatment, not only did both patients gain weight, they also showed improved scores on the Eating Disorder Examination Questionnaire. In addition, a 6-month follow-up showed maintenance of these effects. In this disorder, tandospirone may be an effective drug for long-term use with good patient compliance.
Literature
1.
Arcelus J, Mitchell AJ, Wales J, Nielsen S: Mortality rates in patients with anorexia nervosa and other eating disorders. A meta-analysis of 36 studies. Arch Gen Psychiatry. 2011, 68: 724-731. 10.1001/archgenpsychiatry.2011.74.CrossRefPubMed
2.
Hay PJ, Claudino AM: Clinical psychopharmacology of eating disorders: a research update. Int J Neuropsychopharmacol. 2012, 15: 209-222. 10.1017/S1461145711000460.CrossRefPubMed
3.
Fazeli PK, Calder GL, Miller KK, Misra M, Lawson EA, Meenaghan E, Lee H, Herzog D, Klibanski A: Psychotropic medication use in anorexia nervosa between 1997 and 2009. Int J Eat Disord. 2012, 45 (8): 970-976. 10.1002/eat.22037.PubMedCentralCrossRefPubMed
4.
Hebebrand J: Pharmacotherapy of anorexia nervosa: more questions than answers. J Am Acad Child Adolesc Psychiatry. 2011, 50: 854-856. 10.1016/j.jaac.2011.06.016.CrossRefPubMed
5.
Bailer UF, Kaye WH: Serotonin: imaging findings in eating disorders. Curr Top Behav Neurosci. 2011, 6: 59-79.CrossRefPubMed
6.
Galusca B, Costes N, Zito NG, Peyron R, Bossu C, Lang F, Le Bars D, Estour B: Organic background of restrictive-type anorexia nervosa suggested by increased serotonin 1A receptor binding in right frontotemporal cortex of both lean and recovered patients: [18 F]MPPF PET scan study. Biol Psychiatry. 2008, 64: 1009-1013. 10.1016/j.biopsych.2008.06.006.CrossRefPubMed
7.
Luce KH, Crowther JH: The reliability of the Eating Disorder Examination-Self-Report Questionnaire Version (EDE-Q). The International Journal Of Eating Disorders. 1999, 25: 349-351. 10.1002/(SICI)1098-108X(199904)25:3<349::AID-EAT15>3.0.CO;2-M.CrossRefPubMed
8.
Pineyro G, Blier P: Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev. 1999, 51: 533-591.PubMed
9.
Hamik A, Oksenberg D, Fischette C, Peroutka SJ: Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry. 1990, 28: 99-109. 10.1016/0006-3223(90)90627-E.CrossRefPubMed
10.
Godbout R, Chaput Y, Blier P, de Montigny C: Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine–I. Effects of acute and long-term administration of tandospirone on serotonin neurotransmission. Neuropharmacology. 1991, 30: 679-690. 10.1016/0028-3908(91)90175-B.CrossRefPubMed
11.
12.
13.
14.
Kamijima K, Nakamura J, Tsuboi K, Higuchi T: Review of the efficacy and safety of paroxetine - from the results of post-marketing surveillance. Japanese Journal of Clinical Psychopharmacology. 2007, 10: 1045-1061.
15.
Omori T, Hiramatsu M, Asami Y, Morimasa M, Yamashita N, Houzawa H, Terasawa H, Hasegawa H: Safety and efficacy of J Zoloft® tablets in actual clinical settings: first interim report - findings from drug use result survey and specific drug use result survey for panic disorder. Japanese Journal of Clinical Psychopharmacology. 2012, 15: 561-573.
16.
Brewerton TD: Antipsychotic agents in the treatment of anorexia nervosa: neuropsychopharmacologic rationale and evidence from controlled trials. Curr Psychiatry Rep. 2012, 14: 398-405. 10.1007/s11920-012-0287-6.CrossRefPubMed
Metadata
Title
Tandospirone, a 5-HT1A partial agonist is effective in treating anorexia nervosa: a case series
Authors
Kyoji Okita
Akihiro Shiina
Michiko Nakazato
Masaomi Iyo
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Annals of General Psychiatry / Issue 1/2013
Electronic ISSN: 1744-859X
DOI
https://doi.org/10.1186/1744-859X-12-7

Other articles of this Issue 1/2013

Annals of General Psychiatry 1/2013 Go to the issue

Primary research

Anxiety as a risk factor for school absenteeism: what differentiates anxious school attenders from non-attenders?

Case report

How to diagnose the 22q11.2 deletion syndrome in patients with schizophrenia: a case report

Primary research

Posttraumatic stress disorder and health: a preliminary study of group differences in health and health behaviors

Review

Evidence review and clinical guidance for the use of ziprasidone in Canada

Primary research

Suicidal behaviour among youths associated with psychopathology in both parents and youths attending outpatient psychiatric clinic in Kenya

Primary research

Dysfunction of orbitofrontal and dorsolateral prefrontal cortices in children and adolescents with high-functioning pervasive developmental disorders